Clinical Trials on Mesothelioma in South Africa

Total 45 results

National Cancer Institute (NCI)

Terminated

Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma

Epithelioid Mesothelioma | Sarcomatoid Mesothelioma | Stage IV Pleural Mesothelioma | Recurrent Malignant Mesothelioma | Stage II Pleural Mesothelioma | Stage III Pleural Mesothelioma

United States
Virttu Biologics Limited

Completed

Intrapleural Administration of HSV1716 to Treat Patients With Malignant Pleural Mesothelioma. (1716-12)

Malignant Pleural Mesothelioma

United Kingdom
PrECOG, LLC.
AstraZeneca; University of Sydney; Thoracic Oncology Group Australasia (TOGA)

Active, not recruiting

DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma (DREAM3R)

Mesothelioma | Malignant Pleural Mesothelioma | Pleural Mesothelioma

United States, Australia, New Zealand
Asbestos Diseases Research Foundation
EnGeneIC Limited

Completed

MesomiR 1: A Phase I Study of TargomiRs as 2nd or 3rd Line Treatment for Patients With Recurrent MPM and NSCLC

Non-Small Cell Lung Cancer | Malignant Pleural Mesothelioma

Australia
National Cancer Institute (NCI)

Active, not recruiting

Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma

Epithelioid Mesothelioma | Pleural Malignant Mesothelioma | Sarcomatoid Mesothelioma | Recurrent Malignant Mesothelioma

United States
European Organisation for Research and Treatment...

Active, not recruiting

Nintedanib as Switch Maintenance Treatment of Pleural Malignant Mesothelioma (NEMO)

Malignant Pleural Mesothelioma

United Kingdom, Belgium, Italy
Sheffield Teaching Hospitals NHS Foundation Trust
University of Sheffield; Sheffield Hallam University

Not yet recruiting

Exercise to Boost Immunity in Advanced Cancer (BICEP)

Pancreatic Cancer | Mesothelioma; Lung

United Kingdom
National Cancer Institute (NCI)

Active, not recruiting

Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma

Biphasic Mesothelioma | Epithelioid Mesothelioma | Stage III Pleural Malignant Mesothelioma AJCC v7 | Stage I Pleural Malignant Mesothelioma AJCC v7 | Stage IA Pleural Malignant Mesothelioma AJCC v7 | Stage IB Pleural Malignant Mesothelioma AJCC v7 | Stage II Pleural Malignant Mesothelioma AJCC...

United States
National Cancer Institute (NCI)

Completed

SU5416 in Treating Patients With Malignant Mesothelioma

Malignant Mesothelioma

United States
Wales Cancer Trials Unit
Velindre NHS Trust; June Hancock Mesothelioma Research Fund; Velindre Cancer...

Unknown

A Phase II Trial to Assess TroVax® Plus Chemotherapy in Patients With Malignant Pleural Mesothelioma (SKOPOS)

Mesothelioma | Malignant | Pleural

United Kingdom
MedImmune LLC

Active, not recruiting

Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma (Tremelimumab)

Unresectable Pleural or Peritoneal Malignant Mesothelioma

United States, Italy, Spain, United Kingdom, Belgium, Canada, Poland, France, Korea, Republic of, Hungary, Russian Federation, Germany, Australia, South Africa, Netherlands, Romania, Sweden, Israel, Denmark
Verastem, Inc.

Terminated

Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma (COMMAND)

Malignant Pleural Mesothelioma

United States, Belgium, United Kingdom, Sweden, Italy, Netherlands, France, Japan, Australia, Canada, New Zealand, Norway, Poland, South Africa, Spain
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Gemcitabine and Epirubicin in Treating Patients With Malignant Mesothelioma

Malignant Mesothelioma

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma

Malignant Mesothelioma

United States
Alfacell

Unknown

ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen

Malignant Mesothelioma

United States, Poland, Italy, Germany
National Cancer Institute (NCI)

Recruiting

Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma

Peritoneal Malignant Mesothelioma

United States
AstraZeneca

Recruiting

MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma (eVOLVE-Meso)

Unresectable Pleural Mesothelioma

Denmark, Italy, Australia, Korea, Republic of, Belgium, United States, Canada, Japan, United Kingdom, China, Brazil, France, Taiwan, Spain, Norway, Switzerland, Turkey, Poland, Germany, South Africa, Netherlands
Morphotek

Terminated

Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM) (ARTEMIS)

Mesothelioma, Malignant

France, United Kingdom, United States, Germany, Australia, Italy
Boehringer Ingelheim

Terminated

Nintedanib (BIBF 1120) in Mesothelioma

Mesothelioma

United States, Spain, Canada, United Kingdom, Belgium, Czechia, Sweden, Australia, Germany, Italy, Japan, Russian Federation, Israel, Poland, France, Netherlands, Austria, Mexico, Portugal, Egypt, Argentina, Croatia, Chile, Denmark, Norway and more
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S9810: Gemcitabine Plus Cisplatin in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot Be Removed by Surgery

Malignant Mesothelioma

United States
Trizell Ltd
University of Pennsylvania

Active, not recruiting

Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma (INFINITE)

Malignant Pleural Mesothelioma

France, United States, Australia, Germany, United Kingdom, Russian Federation, Canada, Italy, Poland
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Capecitabine in Treating Patients With Malignant Mesothelioma

Malignant Mesothelioma

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy

Malignant Mesothelioma

United States
Checkpoint Therapeutics, Inc.
Novotech (Australia) Pty Limited

Recruiting

Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers

Melanoma | Renal Cell Carcinoma | Head and Neck Cancer | Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Non Hodgkin Lymphoma | Endometrial Cancer | Carcinoma, Small Cell | Urothelial Carcinoma | Classical Hodgkin Lymphoma | Merkel Cell Carcinoma | Cutaneous Squamous Cell Carcinoma | Malignant Mesothelioma, Advanced

Australia, New Zealand, Thailand, Ukraine, Spain, Russian Federation, France, Poland, South Africa
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

PTK787/ZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma

Malignant Mesothelioma

United States
Bayer

Completed

Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors

Medical Oncology

United States, Italy
Polaris Group

Completed

Ph 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and Cisplatin (ATOMIC)

Mesothelioma

United States, United Kingdom, Taiwan, Australia, Italy
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients (CheckMate743)

Mesothelioma

Brazil, United States, China, Italy, Australia, Belgium, Chile, Colombia, France, Germany, Greece, Japan, Mexico, Netherlands, Poland, Romania, Russian Federation, South Africa, Switzerland, Turkey, United Kingdom
Portsmouth Hospitals NHS Trust
British Lung Foundation; University of Oxford

Completed

Malignant Mesothelioma - Can we Improve Quality of Life (RESPECT-Meso)

Mesothelioma, Malignant

United Kingdom, Australia
Bayer
ImmunoGen and MorphoSys

Completed

Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)

Mesothelioma

Belgium, France, United States, Canada, Spain, Turkey, United Kingdom, Australia, Finland, Italy, Poland, Korea, Republic of, Netherlands, Russian Federation
Seagen Inc.

Terminated

A Study of SGN-CD228A in Advanced Solid Tumors

Colorectal Cancer | Non-small Cell Lung Cancer | Pancreatic Ductal Adenocarcinoma | Cutaneous Melanoma | Pleural Mesothelioma | HER2 Negative Breast Neoplasms

United States, Spain, France, Italy, United Kingdom
Eastern Cooperative Oncology Group
National Cancer Institute (NCI); North Central Cancer Treatment Group

Completed

Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural Mesothelioma

Mesothelioma

United States
Aminex Therapeutics, Inc.

Recruiting

Oral AMXT 1501 Dicaprate in Combination With IV DFMO

Melanoma | Cervical Cancer | Cancer | Breast Cancer | Head and Neck Cancer | Gastric Cancer | Colorectal Cancer | Esophageal Cancer | Solid Tumor | Endometrial Cancer | Advanced Cancer | Diffuse Midline Glioma, H3 K27M-Mutant | Papillary Thyroid Cancer | Solid Carcinoma | Mesotheliomas Pleural | Glioma, Malignant | Ovary Cancer and other conditions

United States, Australia
Multitude Therapeutics Inc.
Tigermed Consulting Co., Ltd

Recruiting

AMT-151 in Patients With Selected Advanced Solid Tumours

Ovarian Cancer | Ovarian Epithelial Cancer | Lung Adenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Triple Negative Breast Cancer | Advanced Solid Tumor | Endometrial Cancer | Advanced Cancer | Ovarian Clear Cell Carcinoma | Pancreatic Ductal Adenocarcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial... and other conditions

China, Australia
Quadriga Biosciences, Inc.
Novotech (Australia) Pty Limited

Completed

Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S

Melanoma | Sarcoma | Kidney Cancer | Cervical Cancer | Breast Cancer | Head and Neck Cancer | Astrocytoma | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Thymic Carcinoma | Lung Cancer | Prostate Cancer | Brain Cancer | Cholangiocarcinoma | Bladder Cancer | Liver Cancer | Brain Metastases | Tongue Cancer | Esophagus... and other conditions

Australia
Western Sydney Local Health District
Bristol-Myers Squibb; University of Western Sydney

Recruiting

Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity (ICEMELT)

Melanoma | Renal Cell Carcinoma | Hepatocellular Carcinoma | Gastric Cancer | Mesothelioma | Endometrial Cancer | Lung Cancer, Nonsmall Cell

Australia
Compass Therapeutics
Iqvia Pty Ltd; Merck, Sharp & Dohme, LLC, Rahway, NJ USA

Recruiting

Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies

Melanoma | Head and Neck Cancer | Small Cell Lung Cancer | Metastatic Cancer | Mesothelioma | Non-small Cell Lung Cancer | Locally Advanced Solid Tumor

United States
NGM Biopharmaceuticals, Inc
Merck Sharp & Dohme LLC

Recruiting

Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Melanoma | Renal Cell Carcinoma | Cervical Cancer | Breast Cancer | Glioblastoma | Gastric Cancer | Colorectal Cancer | Esophageal Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Mesothelioma | Squamous Cell Carcinoma of Head and Neck | Cholangiocarcinoma | Pancreatic Ductal Adenocarcinoma | Endocervical Cancer

United States, Korea, Republic of, Taiwan
Merck Sharp & Dohme LLC

Recruiting

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

Cervical Cancer | Small Cell Lung Carcinoma | Neuroendocrine Tumor | Advanced Solid Tumors | Mesothelioma | Vulvar Cancer | Cholangiocarcinoma | Bile Duct Cancer | Endometrial Cancer | Advanced Cancer | Cervical Carcinoma | Endometrial Carcinoma | Thyroid Carcinoma | Thyroid Cancer | Anal Cancer | Colorectal Carcinoma | Carcinoid... and other conditions

Canada, France, Germany, Italy, Mexico, Netherlands, Poland, Russian Federation, Taiwan, United States, Brazil, Colombia, Israel, Korea, Republic of, Norway, Philippines, South Africa, Spain, Australia, Denmark, Chile, Portugal, Peru
MacroGenics

Terminated

Safety Study of MGD009 in B7-H3-expressing Tumors

Melanoma | Soft Tissue Sarcoma | Clear Cell Renal Cell Carcinoma | Breast Cancer | Pancreatic Cancer | Ovarian Cancer | Prostate Cancer | Non Small Cell Lung Cancer | Mesothelioma | Squamous Cell Carcinoma of the Head and Neck | Bladder Cancer | Colon Cancer | Thyroid Cancer

United States, Australia, Canada
Incyte Corporation

Recruiting

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors

Cervical Cancer | Nasopharyngeal Carcinoma | Mesothelioma | Advanced Solid Tumor | Small-cell Lung Cancer | Esophageal Squamous Cell Carcinoma | Urothelial Carcinoma | Merkel Cell Carcinoma | HepatoCellular Carcinoma | Cutaneous Squamous Cell Carcinoma | MSI-H/dMMR Tumors | PD-L1 Amplified Tumor (9p24.1)

United States, Japan, France, Belgium, Australia
Medicenna Therapeutics, Inc.
Merck Sharp & Dohme LLC

Recruiting

A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1)

Clear Cell Renal Cell Carcinoma | Cervical Cancer | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Fallopian Tube Cancer | Solid Tumor | Squamous Cell Carcinoma of Head and Neck | Bladder Cancer | Skin Cancer | Triple Negative Breast Cancer | Advanced Solid Tumor | Primary Peritoneal Cancer | Endometrial Carcinoma and other conditions

United States, Australia, Korea, Republic of, Canada
Incyte Corporation

Active, not recruiting

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors

Cervical Cancer | Nasopharyngeal Carcinoma | Advanced Solid Tumors | Mesothelioma | Small-cell Lung Cancer | Esophageal Squamous Cell Carcinoma | Merkel Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Anal Carcinoma | Cutaneous Squamous Cell Carcinoma | MSI-H/dMMR Tumors | PD-L1 Amplified Tumor (9p24.1) | Urothelial... and other conditions

Finland, United States, United Kingdom, Belgium, Sweden, Denmark, Norway
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Collecting Tumor Samples From Patients With Gynecological Tumors

Melanoma | Malignant Mesothelioma | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Uterine Corpus Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Serous Cystadenocarcinoma | Gestational Trophoblastic Tumor | Cervical Adenocarcinoma and other conditions

United States
University of Nebraska

Recruiting

Integrated Cancer Repository for Cancer Research (iCaRe2)

Melanoma | Sarcoma | Kidney Cancer | Leukemia | Breast Cancer | Laryngeal Cancer | Hypopharyngeal Cancer | Nasopharyngeal Cancer | Multiple Myeloma | Gastric Cancer | Pancreatic Cancer | Esophageal Cancer | Small Intestine Cancer | Ovarian Cancer | Lynch Syndrome | Lung Cancer | Rectal Cancer | Prostate Cancer | Gastrointestinal... and other conditions

United States

Clinical Trials on Mesothelioma in South Africa

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Algeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations